Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Regeneron Pharmaceuticals Stock Price, Consensus and EPS Surprise REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in ...

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Libtayo Market Evolved, and What Are Its Growth Projections? .Market Growth from 2024 to 2025: oThe Libtayo ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Meghan Markle took to Instagram on Tuesday to announce the name of her brand new lifestyle brand. “Some of you may have heard whispers about what I’ve been creating. In two weeks, my series on ...

Maintaining brand consistency is essential for building trust and recognition among consumers, but many marketers unknowingly sabotage their own efforts. From misaligned messaging to chasing ...